Dynamk Capital
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Dynamk Capital.
Key people at Dynamk Capital.
Key people at Dynamk Capital.
Dynamk Capital is a New York City–based venture capital firm dedicated to investing in early-stage companies within the life sciences sector, particularly focusing on biotechnology, pharmaceuticals, medical devices, and life science industrials such as tools, technologies, and services critical to discovery, development, and manufacturing. Their mission centers on funding the future of life sciences by supporting innovative companies that advance healthcare and biological research. The firm partners closely with entrepreneurs to help them scale businesses with strong product-market fit and scalable models, contributing significantly to the growth and innovation of the life sciences startup ecosystem[1][2][6][7].
Founded in 2017, Dynamk Capital was established by key partners including Daniella Kranjac and Mario M. Kranjac, who bring expertise in venture investing and life sciences. Since its inception, the firm has evolved to specialize in early-stage investments globally, focusing on companies that develop critical life science industrial tools and technologies. Over time, Dynamk Capital has built a portfolio of over 16 investments, including notable companies like Alpenglow Biosciences, Virica Biotech, and RoosterBio, marking pivotal moments in their growth through strategic partnerships and technological advancements[1][5][6].
Dynamk Capital rides the wave of increasing demand for advanced life sciences solutions driven by global health challenges, technological breakthroughs in biotechnology, and the growing need for precision medicine and diagnostics. The timing is critical as the life sciences sector experiences rapid innovation in AI-enabled diagnostics, cell therapies, and novel drug development platforms. By investing in enabling technologies and industrial tools, Dynamk Capital influences the broader ecosystem by accelerating the development pipeline and manufacturing capabilities essential for next-generation therapies and diagnostics[6][7].
Looking ahead, Dynamk Capital is poised to deepen its impact by continuing to back cutting-edge life sciences startups that address unmet medical needs and improve healthcare outcomes. Trends such as AI integration in diagnostics, scalable cell therapy manufacturing, and personalized medicine will shape their investment focus. Their influence is likely to grow as they foster collaborations between startups and established industry players, driving innovation from early discovery through commercialization. Dynamk Capital’s commitment to life science industrials positions them uniquely to support the infrastructure that underpins the future of healthcare innovation[6][7].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2025 | Savant Labs | $19.0M Series A | — | Cota Capital |
| Sep 1, 2023 | CellFE | $22.0M Series A | — | Canvas Ventures, Celesta, Cota Capital, Menlo Ventures |
| Jun 1, 2023 | Vernal Biosciences | $20.0M Series A | — | — |
| Feb 1, 2023 | Savant Labs | $11.0M Seed | — | Cota Capital |
| Jun 1, 2022 | Vernal Biosciences | $21.0M Series A | — | — |
| Apr 1, 2022 | Bionter | $3.0M Seed | — | — |
| Dec 1, 2021 | Curi Bio | $10.0M Series A | — | — |
| Jun 1, 2021 | Vectron Biosolutions | $3.0M Series A | — | — |
| Jun 1, 2021 | Alpenglow Biosciences | $4.0M Series A | — | — |
| Mar 1, 2021 | Curi Bio | $6.0M Series A | — | — |
| Sep 1, 2020 | Lucid Scientific | $3.0M Seed | — | — |
| Jan 1, 2020 | CellFE | $5.0M Seed | — | Canvas Ventures, Celesta, Cota Capital, Menlo Ventures |
